TrialBMC medicine2025

Nimotuzumab combined with docetaxel and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: a multicenter, phase 2 trial.

Qihua Zou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.